Characterization of the Heparin/Heparan Sulfate Binding Site of the Natural Cytotoxicity Receptor NKp46†
Identifieur interne : 002F75 ( Main/Merge ); précédent : 002F74; suivant : 002F76Characterization of the Heparin/Heparan Sulfate Binding Site of the Natural Cytotoxicity Receptor NKp46†
Auteurs : Alon Zilka [Israël] ; Guy Landau [Israël] ; Oren Hershkovitz [Israël] ; Noga Bloushtain [Israël] ; Ahuva Bar-Ilan [Israël] ; Fabrice Benchetrit [Israël] ; Eyal Fima [Israël] ; Toin H. Van Kuppevelt [Israël] ; John T. Gallagher [Israël] ; Sharona Elgavish [Israël] ; Angel Porgador [Israël]Source :
- Biochemistry [ 0006-2960 ] ; 2005.
Abstract
NKp46 is a member of a group of receptors collectively termed natural cytotoxicity receptors (NCRs) that are expressed by natural killer (NK) cells. NCRs are capable of mediating direct killing of tumor and virus-infected cells by NK cells. We have recently shown that NKp46 recognizes the heparan sulfate moieties of membranal heparan sulfate proteoglycans (HSPGs), thus enabling lysis of tumor cells by NK cells. In the current study, we further examined the residues in NKp46 that may be involved in heparan sulfate binding on tumor cells. On the basis of both the electrostatic potential map and comparison to the heparin binding site on human fibronectin, we predicted a continuous region containing the basic amino acids K133, R136, H139, R142, and K146 to be involved in NKp46 binding to heparan sulfate. Mutating these amino acids on NKp46D2 to noncharged amino acids retained its virus binding capacity but reduced its binding to tumor cells with a 10−100 fold lower KD when tested for direct binding to heparin. The minimal length of the heparin/heparan sulfate epitope recognized by NKp46 was eight saccharides as predicted from the structure and proven by testing heparin oligomers. Testing selectively monodesulfated heparin oligomers emphasized the specific contributions of O-sulfation, N-sulfation, and N-acetylation to epitope recognition by NKp46. The characterization of heparan sulfate binding region in NKp46 offers further insight into the identity of the ligands for NKp46 and the interaction of NK and cancers.
Url:
DOI: 10.1021/bi051241s
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000871
- to stream Istex, to step Curation: 000871
- to stream Istex, to step Checkpoint: 000A57
Links to Exploration step
ISTEX:5FAA5D798F3882D8996FDF98C2E4917BAC44185CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Characterization of the Heparin/Heparan Sulfate Binding Site of the Natural Cytotoxicity Receptor NKp46†</title>
<author><name sortKey="Zilka, Alon" sort="Zilka, Alon" uniqKey="Zilka A" first="Alon" last="Zilka">Alon Zilka</name>
</author>
<author><name sortKey="Landau, Guy" sort="Landau, Guy" uniqKey="Landau G" first="Guy" last="Landau">Guy Landau</name>
</author>
<author><name sortKey="Hershkovitz, Oren" sort="Hershkovitz, Oren" uniqKey="Hershkovitz O" first="Oren" last="Hershkovitz">Oren Hershkovitz</name>
</author>
<author><name sortKey="Bloushtain, Noga" sort="Bloushtain, Noga" uniqKey="Bloushtain N" first="Noga" last="Bloushtain">Noga Bloushtain</name>
</author>
<author><name sortKey="Bar Ilan, Ahuva" sort="Bar Ilan, Ahuva" uniqKey="Bar Ilan A" first="Ahuva" last="Bar-Ilan">Ahuva Bar-Ilan</name>
</author>
<author><name sortKey="Benchetrit, Fabrice" sort="Benchetrit, Fabrice" uniqKey="Benchetrit F" first="Fabrice" last="Benchetrit">Fabrice Benchetrit</name>
</author>
<author><name sortKey="Fima, Eyal" sort="Fima, Eyal" uniqKey="Fima E" first="Eyal" last="Fima">Eyal Fima</name>
</author>
<author><name sortKey="Van Kuppevelt, Toin H" sort="Van Kuppevelt, Toin H" uniqKey="Van Kuppevelt T" first="Toin H." last="Van Kuppevelt">Toin H. Van Kuppevelt</name>
</author>
<author><name sortKey="Gallagher, John T" sort="Gallagher, John T" uniqKey="Gallagher J" first="John T." last="Gallagher">John T. Gallagher</name>
</author>
<author><name sortKey="Elgavish, Sharona" sort="Elgavish, Sharona" uniqKey="Elgavish S" first="Sharona" last="Elgavish">Sharona Elgavish</name>
</author>
<author><name sortKey="Porgador, Angel" sort="Porgador, Angel" uniqKey="Porgador A" first="Angel" last="Porgador">Angel Porgador</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5FAA5D798F3882D8996FDF98C2E4917BAC44185C</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1021/bi051241s</idno>
<idno type="url">https://api.istex.fr/ark:/67375/TPS-XC1SB6GX-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000871</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000871</idno>
<idno type="wicri:Area/Istex/Curation">000871</idno>
<idno type="wicri:Area/Istex/Checkpoint">000A57</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A57</idno>
<idno type="wicri:doubleKey">0006-2960:2005:Zilka A:characterization:of:the</idno>
<idno type="wicri:Area/Main/Merge">002F75</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Characterization of the Heparin/Heparan Sulfate Binding Site of the Natural
Cytotoxicity Receptor NKp46<ref type="bib" target="#bi051241sAF2">†</ref>
</title>
<author><name sortKey="Zilka, Alon" sort="Zilka, Alon" uniqKey="Zilka A" first="Alon" last="Zilka">Alon Zilka</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Landau, Guy" sort="Landau, Guy" uniqKey="Landau G" first="Guy" last="Landau">Guy Landau</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Hershkovitz, Oren" sort="Hershkovitz, Oren" uniqKey="Hershkovitz O" first="Oren" last="Hershkovitz">Oren Hershkovitz</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Bloushtain, Noga" sort="Bloushtain, Noga" uniqKey="Bloushtain N" first="Noga" last="Bloushtain">Noga Bloushtain</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Bar Ilan, Ahuva" sort="Bar Ilan, Ahuva" uniqKey="Bar Ilan A" first="Ahuva" last="Bar-Ilan">Ahuva Bar-Ilan</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Benchetrit, Fabrice" sort="Benchetrit, Fabrice" uniqKey="Benchetrit F" first="Fabrice" last="Benchetrit">Fabrice Benchetrit</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Fima, Eyal" sort="Fima, Eyal" uniqKey="Fima E" first="Eyal" last="Fima">Eyal Fima</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Van Kuppevelt, Toin H" sort="Van Kuppevelt, Toin H" uniqKey="Van Kuppevelt T" first="Toin H." last="Van Kuppevelt">Toin H. Van Kuppevelt</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Gallagher, John T" sort="Gallagher, John T" uniqKey="Gallagher J" first="John T." last="Gallagher">John T. Gallagher</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Elgavish, Sharona" sort="Elgavish, Sharona" uniqKey="Elgavish S" first="Sharona" last="Elgavish">Sharona Elgavish</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Porgador, Angel" sort="Porgador, Angel" uniqKey="Porgador A" first="Angel" last="Porgador">Angel Porgador</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Microbiology and Immunology, Faculty of Health Sciences, and Cancer Research Center, Ben Gurion Universityof the Negev, Beer Sheva 84105, Israel, Department of Biochemistry, University Medical Center, NCMLS, Nijmegen, TheNetherlands, Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie, Hospital NHS Trust,Manchester M204BX, United Kingdom, and The Bioinformatics Unit, The Hebrew UniversityHadassah Medical School,Jerusalem 91120</wicri:regionArea>
<wicri:noRegion>Jerusalem 91120</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Israël</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Biochemistry</title>
<title level="j" type="abbrev">Biochemistry</title>
<idno type="ISSN">0006-2960</idno>
<idno type="eISSN">1520-4995</idno>
<imprint><publisher>American Chemical Society</publisher>
<date type="e-published">2005</date>
<date type="published">2005</date>
<biblScope unit="vol">44</biblScope>
<biblScope unit="issue">44</biblScope>
<biblScope unit="page" from="14477">14477</biblScope>
<biblScope unit="page" to="14485">14485</biblScope>
</imprint>
<idno type="ISSN">0006-2960</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0006-2960</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">NKp46 is a member of a group of receptors collectively termed natural cytotoxicity receptors (NCRs) that are expressed by natural killer (NK) cells. NCRs are capable of mediating direct killing of tumor and virus-infected cells by NK cells. We have recently shown that NKp46 recognizes the heparan sulfate moieties of membranal heparan sulfate proteoglycans (HSPGs), thus enabling lysis of tumor cells by NK cells. In the current study, we further examined the residues in NKp46 that may be involved in heparan sulfate binding on tumor cells. On the basis of both the electrostatic potential map and comparison to the heparin binding site on human fibronectin, we predicted a continuous region containing the basic amino acids K133, R136, H139, R142, and K146 to be involved in NKp46 binding to heparan sulfate. Mutating these amino acids on NKp46D2 to noncharged amino acids retained its virus binding capacity but reduced its binding to tumor cells with a 10−100 fold lower KD when tested for direct binding to heparin. The minimal length of the heparin/heparan sulfate epitope recognized by NKp46 was eight saccharides as predicted from the structure and proven by testing heparin oligomers. Testing selectively monodesulfated heparin oligomers emphasized the specific contributions of O-sulfation, N-sulfation, and N-acetylation to epitope recognition by NKp46. The characterization of heparan sulfate binding region in NKp46 offers further insight into the identity of the ligands for NKp46 and the interaction of NK and cancers.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002F75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:5FAA5D798F3882D8996FDF98C2E4917BAC44185C |texte= Characterization of the Heparin/Heparan Sulfate Binding Site of the Natural Cytotoxicity Receptor NKp46† }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |